Jeff Bezos invests in the quest for immortality

Jeff Bezos wants to delay ageing, quite literally. Multi-billionaire has become an investor in Altos Labs, an anti-aging technology startup, reports MIT Tech Review.

Altos Labs is studying the aging process and developing technology that can reprogram human cells to combat aging. The research is based on the developments of the Japanese scientist Yamanaka Shinyi, who received the Nobel Prize for his discoveries.

The center’s specialists plan to create a way to extend human life by 50 years.

Little is known about the company. The report said the start-up was set in the US and UK this year following a biotechnology-oriented conference that was held in the Los Altos Hills.

According to the MIT Tech Review, a securities disclosure filed in California in June indicates the company has raised at least $270 million (€227 million).

The company also reportedly plans to set up in multiple locations including San Diego, Japan, and Cambridge in the UK.

Bezos is said to have a fairly long-standing interest in longevity research, and he previously invested in an anti-aging company called Unity Biotechnology.

Do you think it’s a noble goal to pursue immortality? We would love to hear in the comments.

Greetings, explorer! We thank our supporters from the bottom of our hearts for their generous donations that keep anomalien.com alive. If you'd like to join the cause and help us continue to deliver amazing articles, please consider making a donation. Let's keep the 👽 smiling!

Follow us on Instagram, Twitter and Telegram for interesting and mysterious bonus content!

Default image
Jake Carter

Jake Carter is a journalist and a paranormal investigator who has been fascinated by the unexplained since he was a child.

He is not afraid to challenge the official narratives and expose the cover-ups and lies that keep us in the dark. He is always eager to share his findings and insights with the readers of anomalien.com, where he has been a regular contributor since 2013.

Leave a Reply